×
About 478 results

ALLMedicine™ Allergy Immunotherapy Center

Research & Reviews  138 results

Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: subg...
https://doi.org/10.1016/j.jaci.2023.02.024
The Journal of Allergy and Clinical Immunology; Contoli M, Porsbjerg C et. al.

Mar 6th, 2023 - Randomised controlled trials (RCTs) have demonstrated the efficacy of allergy immunotherapy (AIT) in allergic rhinitis (AR) and the disease-modifying effects of the SQ grass sublingual immunotherapy (SLIT)-tablet. To assess real-world, long-term e...

Allergy immunotherapy: Literature Review 2022.
https://doi.org/10.1016/j.anai.2022.10.020
Annals of Allergy, Asthma & Immunology : Official Publica... Nelson HS

Feb 4th, 2023 - Allergy immunotherapy: Literature Review 2022.|2023|Nelson HS,|therapy,therapeutic use,

Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
https://clinicaltrials.gov/ct2/show/NCT04296474

Sep 21st, 2022 - Bakground: Intralymphatic immunotherapy has been proposed as a new, more effective, modality for allergy immunotherapy. With ultrasound- guided injections into the lymph node the allergen is injected directly to the secondary lymphoid organ to sti...

Is allergy immunotherapy-induced anaphylaxis still a real problem?
https://doi.org/10.1097/ACI.0000000000000852
Current Opinion in Allergy and Clinical Immunology; Bernstein DI, Berendts K

Aug 19th, 2022 - The current review describes the incidence and risk for anaphylaxis due to allergy injections. The incidence of fatal anaphylaxis occurs with approximately one in 7.2 million injection visits. Severe anaphylaxis may occur once in every 160 000 vis...

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
https://clinicaltrials.gov/ct2/show/NCT05476484

Jul 27th, 2022 - Allergic rhinitis (AR) is an inflammatory disorder, characterised by pruritus, sneezing, rhinorrhoea, and nasal congestion. It is one of the most common disorders worldwide, with an estimated global prevalence of 10-30%. AR is a chronic and progre...

see more →

Clinicaltrials.gov  13 results

Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
https://clinicaltrials.gov/ct2/show/NCT04296474

Sep 21st, 2022 - Bakground: Intralymphatic immunotherapy has been proposed as a new, more effective, modality for allergy immunotherapy. With ultrasound- guided injections into the lymph node the allergen is injected directly to the secondary lymphoid organ to sti...

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
https://clinicaltrials.gov/ct2/show/NCT05476484

Jul 27th, 2022 - Allergic rhinitis (AR) is an inflammatory disorder, characterised by pruritus, sneezing, rhinorrhoea, and nasal congestion. It is one of the most common disorders worldwide, with an estimated global prevalence of 10-30%. AR is a chronic and progre...

Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants
https://clinicaltrials.gov/ct2/show/NCT04104828

Mar 23rd, 2022 - This pilot study is an observational study with subsequent use of coded biological material. The blood sera are collected and prepared at the Allergy Units at the University Hospital Zurich (USZ) or Centre for Rhinology and Allergology Wiesbaden (...

Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis
https://clinicaltrials.gov/ct2/show/NCT02014623

Oct 14th, 2020 - Allergic diseases represent a major health issue worldwide and epidemiological studies in Melbourne, Australia, have reported a high prevalence of rhinitis (hayfever) and atopy (genetic tendency to make allergy antibody) in Asian and Caucasian sub...

Allergy Immunotherapy for the Reduction of Asthma
https://clinicaltrials.gov/ct2/show/NCT01028560

May 28th, 2019 - In this clinical study we aim to determine the effect of allergy immunotherapy in decreasing asthma and allergy related disease in children who had multiple episodes of wheezing and who are at high risk for developing persisting asthma. These risk...

see more →

News  40 results

Mobile Health Apps Provide Complementary Approach to Rhinitis and Rhinosinusitis Management
https://www.medscape.com/viewarticle/985131

Dec 6th, 2022 - Published evidence from a handful of mobile health apps show their potential to assist in the diagnosis of rhinitis and rhinosinusitis as well as to evaluate management and treatment adherence for these conditions, a new report suggests. Despite t...

Allergists Seek to Bolster Adherence to Shots, Sublingual Drops Treatments
https://www.medscape.com/viewarticle/981383

Sep 26th, 2022 - Two new studies highlight the challenges for patients in sticking with allergy shots or sublingual immunotherapy. Both studies add to arguments in favor of having frank discussions before selecting these options and of making it easier to complete...

Oral Immunotherapy: Psychological Support Improves Treatment Success
https://www.medscape.com/viewarticle/969956

Mar 9th, 2022 - Oral immunotherapy (OIT) is a promising long-term food allergy regimen, but it can be so stressful that patients often quit. Providing young patients and their families with psychological support can increase the odds that they'll complete the ful...

Debate Continues Over Multiallergen Subcutaneous Immunotherapy
https://www.medscape.com/viewarticle/963870

Nov 30th, 2021 - A resolution is needed in the ongoing controversy between US and European allergists over the best approach to subcutaneous allergy immunotherapy (SCIT), "since it is likely that one or the other group of patients is receiving sub-optimal treatmen...

There's a Much Safer Food Allergy Immunotherapy. Why Don't More Doctors Offer It?
https://www.medscape.com/viewarticle/954302

Jul 7th, 2021 - This is part 1 of a three-part series. Part 2 is here. Part 3 is here. For the 32 million people in the United States with food allergies, those who seek relief beyond constant vigilance and EpiPens face a confusing treatment landscape. In January...

see more →